A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Cancer

Volumn 119, Issue 21, 2013, Pages 3797-3804

  Grant, Barbara W ^a   Jung, Sin Ho ^b   Johnson, Jeffrey L ^c   Kostakoglu, Lale ^d   Hsi, Eric ^e   Byrd, John C ^f   Jones, Jeffrey ^f   Leonard, John P ^g   Martin, S Eric ^h   Cheson, Bruce D ⁱ  

^a UNIVERSITY OF VERMONT   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h CHRISTIANA CARE HEALTH SYSTEM   (United States)

ⁱ GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

epratuzumab; FLIPI score; follicular lymphoma; monoclonal antibody; rituximab

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPRATUZUMAB; FC RECEPTOR; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON REGULATORY FACTOR 4; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERSENSITIVITY; HYPOTENSION; HYPOXIA; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; THROMBOSIS; TREATMENT RESPONSE; URTICARIA; VOMITING;

EPRATUZUMAB; FLIPI SCORE; FOLLICULAR LYMPHOMA; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84886087868     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28299     Document Type: Article

References (41)

1. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cylophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 3725-3732.
2. Marcus RE, Imrie K, Solal-Celigny P, et al. A phase III study of rituximab plus CVP versus CVP alone in patients with previously untreated advanced follicular lymphoma: updated results with 53 months' median follow-up and analysis of outcomes according to baseline prognostic factors. J Clin Oncol. 2008; 26: 4579-4586.
3. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study. J Clin Oncol. 2007; 25: 1986-1992.
4. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with weekly x 4 schedule. Blood. 2004; 103: 4416-4423.
5. Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2012; 23: 2356-2310.
6. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosis. Arthritis Res Ther. 2010; 12: R204.
7. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006; 24: 3880-3886.
8. Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011; 118: 4053-4061.
9. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 3051-3059.
10. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008; 113: 2714-2723.
11. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005; 23: 4390-4398.
12. Leonard JP, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (anti-CD80) monoclonal antibody in combination with rituximab for relapsed or refractory follicular lymphoma. Ann Oncol. 2007; 18: 1216-1223.
13. Simon R,. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials. 1989; 10: 1-10.
14. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 1244-1253.
15. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.
16. Meignan M, Gallamini A, Haioun C,. Report on the first International Workshop on Interim-PET-scan in lymphoma. Leuk Lymphoma. 2009; 50: 1257-1260.
17. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99: 754-758.
18. Naresh KN,. MUM1 expression dichotomises follicular lymphoma into predominately MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica. 2007; 92: 267-268.
19. Sweetenham JW, Goldman BH, LeBlanc ML, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group study. Ann Oncol. 2010; 21: 1196-1202.
20. Farinha P, Campo E, Banham AH, et al. The architecural pattern of FOXP3+ T cells is an important predictor of survival in patients with follicular lymphoma. Med Pathol. 2006; 19: 224A.
21. Kelley T, Nech R, Absi A, Jin T, Pohlman B, Hsi E,. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma. 2007; 48: 2403-2411.
22. Jung SH, Kim KM,. On the estimation of the binomial probability in multistage clinical trials. Stat Med. 2004; 23: 881-896.
23. Jennison C, Turnbull BW,. Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics. 1983; 25: 49-58.
24. Jung SH, Owzar KM, George SL, Lee TY,. P-value calculation for multistage phase II cancer clinical trials (with discussion). J Biopharm Stat. 2006; 16: 756-783.
25. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 412-417.
26. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two differnet schedules in trial SAKK 35/98. J Clin Oncol. 2010; 28: 4480-4484.
27. Watanabe T, Tobinai K, Shibata T, et al. Phase II/III study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) versus two-week R-CHOP (R-CHOP-14) for untreated indolent B-cell non-Hodgkin lymphoma: Japan Clinical Oncology Group (JCOG) 0203 trial. J Clin Oncol. 2011; 29: 3990-3998.
28. Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. J Clin Oncol. 2012; 30: Abstract 3.
29. Deneys V, Mazzon AM, Marques JL, Benoit H, De Bruyere M,. Reference values for periphearl blood B-lymphocyte subpopulations: a basis for multiparametric immunophenotyping of abnormal lymphocytes. J Immunol Methods. 2001; 253: 23-36.
30. Huang J, Fan G, Zhong Y, et al. Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol. 2005; 123: 828-832.
31. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003; 9 (10 pt 2): 3982S-3990S.
32. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007; 44: 1331-1334.
33. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351: 2159-2169.
34. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an advers prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008; 26: 440-446.
35. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory cells are associated with improved overall survival in follicular lymphoma. Blood. 2006; 108: 2957-2964.
36. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophages (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005; 106: 2169-2174.
37. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD,. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010; 28: 2902-2913.
38. Persky DO, Dornan D, Goldman BH, et al. Fc gamma receptor 3a genotype predicts ovearll survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 2012; 97: 937-942.
39. Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011; 29: 3194-3200.
40. Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography in treated grade 1 and follicular lymphoma. Leuk Lymphoma. 2007; 48: 1548-1555.
41. Zinzani PL, Musuraca G, Alinari L, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymp Leuk Myeloma. 2007; 7: 291-295.